Citations

Clear

3138 citation(s) found for "Smith, AM".

Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
Liu, Minetta C. , Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Smith, David A. , Curtis, Christina , Williams, Richard T. , Hartman, Anne‐Renee , Baselga, José, Aravanis, Alexander M. , Hubbell, Earl , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Couch, Fergus J. , Klein, Eric A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2018.36.15_suppl.536 Get It

A method to reduce variability in scoring antibody-mediated rejection in renal allografts: implications for clinical trials - a retrospective study
Smith, Byron H. , Cornell, Lynn D. , Cortese, Cherise , Geiger, Xochiquetzal J., Alexander, Mariam P., Ryan, Margaret , Park, Walter D. , Morales-Álvarez, Martha Catalina , Kremers, Walter K. , Stegall, Mark D. , Smith, Byron , Geiger, Xochiquetzal, Park, Walter, Morales Alvarez, Martha Catalina, Stegall, Mark, Stegall, Mark D , Park, Walter , Cornell, Lynn , Kremers, Walter K , Smith, Maxwell L. , Schinstock, Carrie A.

Mayo Clinic

Transplant International | September 4, 2018 | Volume: 32 | Issue: 2 | Pages: 173-183

10.1111/tri.13340 | PMID 30179275 Get It

Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission
Auvin, Stéphane , Donald, Kirsten A. , Hartmann, Hans , Valente, Kette D. , Bogaert, Patrick Van , Cross, J. Helen , Ōsawa, Makiko, Kanemura, Hideaki , Aihara, Masao, Guerreiro, Marilisa M. , Vinayan, Kollencheri Puthenveettil , Smith, Mary Lou , Carmant, Lionel, Kerr, Michael , Dunn, David , Wilmshurst, Jo M. , Berl, Madison , Kanemura, Hideaki , Wilmshurst, Jo M , Auvin, Stéphane , Cross, Helen J , Valente, Kette , Wirrell, Elaine , Berl, Madison M. , Samia, Pauline , Hermann, Bruce P.

Mayo Clinic

Epilepsia | September 4, 2018 | Volume: 59 | Issue: 10 | Pages: 1867-1880

10.1111/epi.14549 | PMID 30178479 Get It

SummaryAttention‐deficit/hyperactivity disorder (ADHD) is a common and challenging comorbidity affecting many children with epilepsy. A working group under the International League Against Epilepsy (ILAE) Pediatric Commission identified key questions on the identification and management of ADHD in children with epilepsy. Systematic reviews of the evidence to support approaches to these questions were collated and graded using criteria from the American Academy of Neurology Practice Parameter. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) requirements were followed, with PROSPERO registration (CRD42018094617). No increased risk of ADHD in boys with epilepsy compared to girls with epilepsy was found (Level A). Valproate use in pregnancy is associated with inattentiveness and hyperactivity in offspring (1 class I study), and children with intellectual and developmental disabilities are at increased risk of ADHD (Level A). Impact of early seizure onset on development of ADHD was unclear (Level U), but more evident with poor seizure control (Level B). ADHD screening should be performed from 6 years of age, or at diagnosis, and repeated annually (Level U) and reevaluated after change of antiepileptic drug (AED) (Level U). Diagnosis should involve health practitioners with expert training in ADHD (Level U). Use of the Strength and Difficulties Questionnaire screening tool is supported (Level B). Formal cognitive testing is strongly recommended in children with epilepsy who are struggling at school (Level U). Behavioral problems are more likely with polytherapy than monotherapy (Level C). Valproate can exacerbate attentional issues in children with childhood absence epilepsy (Level A). Methylphenidate is tolerated and effective in children with epilepsy (Level B). Limited evidence supports that atomoxetine is tolerated (Level C). Multidisciplinary involvement in transition and adult ADHD clinics is essential (Level U). In conclusion, although recommendations could be proposed for some of the study questions, this systematic review highlighted the need for more comprehensive and targeted large‐population prospective studies.
A framework for quality measurement in the presurgical care of chronic rhinosinusitis: a review from the Quality Improvement Committee of the American Rhinologic Society
Mattos, José L. , Rudmik, Luke , Manes, Peter R., Lee, Jivianne, Schneider, John S. , Setzen, Michael, Parasher, Arjun K. , Smith, Timothy L. , Stokken, Janalee K., Stokken, Janalee K. , Smith, Timothy L , Carlson, Matthew L , Mattos, Jose , Soler, Zachary M. , Higgins, Thomas S , Lee, Jivianne T.

Mayo Clinic

International Forum of Allergy & Rhinology | September 3, 2018 | Volume: 8 | Issue: 12 | Pages: 1380-1388

10.1002/alr.22154 | PMID 30175899 Get It

BackgroundQuality improvement (QI) in the management of chronic rhinosinusitis (CRS) is garnering increasing attention. Defining frameworks and metrics to assess the quality of key components in CRS management could assist in reducing unwarranted practice variation and increase high‐quality care.MethodsA panel of the American Rhinologic Society (ARS) QI committee reviewed the literature to determine important presurgical components of CRS care that warrant QI. The evidence was organized into 4 categories: (1) diagnosis, (2) medical management, (3) appropriate patient selection for surgery, and (4) patient‐centered discussion. The combination of these categories was used to develop a framework termed the CRS Appropriate Presurgical Algorithm (CAPA).ResultsPrior to offering surgery for CRS, the best available evidence support the following quality metrics: (1) a guideline‐based diagnosis should be confirmed; (2) appropriate medical management, including a minimum of topical corticosteroid therapy and saline irrigations, should have been attempted (assuming patient tolerance); (3) a computed tomography (CT) scan should be obtained (to confirm the presence of sinus inflammation and for surgical planning); and (4) a patient‐centered discussion regarding treatment options for refractory CRS (ie, alternative medical therapies vs surgery vs observation) while focusing on risks and benefits, the need for long‐term medical compliance, and understanding of patient preferences and expectations.ConclusionDefining metrics that assess key components to CRS care prior to offering surgery has the potential to further improve upon an already successful treatment paradigm, reduce unwarranted practice variation, and to ensure that patients are receiving a similar level of high‐quality care.
Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents
Hanson, Andrew C. , Rihal, Charanjit S. , Gulati, Rajiv , Bell, Malcolm R. , Nuttall, Gregory A. , Smith, Bradford B. , Warner, Matthew A. , Warner, Nafisseh S. , Smith, Mark M. , Rihal, Charanjit S.

Mayo Clinic

Anesthesia & Analgesia | August 31, 2018 | Volume: 128 | Issue: 4 | Pages: 621-628

10.1213/ane.0000000000003408 | PMID 30169404 Get It

BACKGROUND: Noncardiac surgery (NCS) following percutaneous coronary intervention (PCI) with stenting is sometimes associated with major adverse cardiac events (MACEs). Second-generation drug-eluting stents (DES) were developed to decrease the incidence of MACE seen with bare metal and first-generation DES. METHODS: The medical records of all adult patients who underwent second-generation DES placement between July 29, 2008 and July 28, 2011 followed by NCS between September 22, 2008 and July 1, 2013 were reviewed. All episodes of MACE following surgery were recorded. RESULTS: A total of 282 patients (74.8% male) were identified who underwent NCS after PCI with second-generation DES. MACE occurred in 15 patients (5.3%), including 11 deaths. The incidence of MACE changed significantly with time from PCI to NCS: 17.1%, 10.0%, 0.0%, and 3.1% for patients undergoing NCS at 0–90, 91–180, 181–365, and ≥366 days, respectively. Compared with those having NCS ≥366 days after PCI, the odds ratio for MACE (95% confidence interval) was 6.4 (1.9 to 21.3) at 0–90 days and 3.4 (0.8 to 15.3) at 91–180 days. Seven days prior to NCS, 146 (52%) patients were on dual antiplatelet therapy (DAPT), 106 (38%) were on aspirin, and 30 (11%) did not receive antiplatelet therapy. Excessive surgical bleeding occurred in 19 cases (6.7%). While observed bleeding rates were lowest in those not receiving antiplatelet therapy, there were no statistically significant differences based on the presence or absence of antiplatelet therapy (3% [1/30] for no antiplatelet therapy compared to 6% [6/106] for aspirin monotherapy and 8% [12/146] for DAPT; Fisher exact test: P = .655). CONCLUSIONS: The incidence of MACE in patients with second-generation DES undergoing NCS was 5.3% and was highest in the first 180 days following DES implantation. The rate of excessive surgical bleeding was 6.7% with the highest observed rate in those on DAPT. However, differences by the presence or absence of antiplatelet therapy were not significant, and future large observational studies will be necessary to further define bleeding risk with continued DAPT.
1094Machine-learning algorithm utilizing serial high-sensitivity cardiac troponin I concentrations for ruling-out acute myocardial infarction
Sandoval, Yader , Sexter, Anne, Schulz, Karen , Apple, F, Smith, Stephen W. , Apple, F

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.1094 Get It

Interscalene Brachial Plexus Block
Amundson, Adam W. , Smith, Hugh M.

Mayo Clinic

Anesthesiology | August 24, 2018 | Volume: 129 | Issue: 6 | Pages: 1166-1166

10.1097/aln.0000000000002410 | PMID 30142089 Get It

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Bottomley, Andrew , Pe, Madeline , Sloan, Jeff A. , Basch, Ethan , Bonnetain, Franck, Calvert, Melanie , Campbell, Alicyn, Cleeland, Charles S. , Cocks, Kim , Collette, Laurence , Dueck, Amylou C. , Flechtner, Hans‐Henning , Gotay, Carolyn , Greimel, Eva , Griebsch, Ingolf , Grøenvold, Mogens , Hamel, Jean-François, King, Madeleine , Koller, Michael , Malone, Daniel C. , Martinelli, Francesca , Moinpour, Carol M. , Musoro, Jammbe , O’Connor, Daniel , Oliver, Kathy , Piault‐Louis, Elisabeth, Piccart, Martine , Pimentel, Francisco , Quinten, Chantal , Reijneveld, Jaap C. , Soltys, Katherine M, Sridhara, Rajeshwari , Taphoorn, Martin , Velikova, Galina , Coens, Corneel , Sloan, Jeff, Flechtner, Hans-Henning , Dueck, A. C. , Basch, Ethan , Devlin, Nancy J. , Kluetz, Paul Gustav , Mitchell, Sandra A , Schürmann, Christoph, Smith, Ashley Wilder

Mayo Clinic

Clinical Trials | August 24, 2018 | Volume: 15 | Issue: 6 | Pages: 624-630

10.1177/1740774518795637 | PMID 30141714 Get It

Background There is currently a lack of consensus on how health-related quality of life and other patient-reported outcome measures in cancer randomized clinical trials are analyzed and interpreted. This makes it difficult to compare results across randomized controlled trials (RCTs) synthesize scientific research, and use that evidence to inform product labeling, clinical guidelines, and health policy. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials (SISAQOL) Consortium aims to develop guidelines and recommendations to standardize analyses of patient-reported outcome data in cancer RCTs. Methods and Results Members from the SISAQOL Consortium met in January 2017 to discuss relevant issues. Data from systematic reviews of the current state of published research in patient-reported outcomes in cancer RCTs indicated a lack of clear reporting of research hypothesis and analytic strategies, and inconsistency in definitions of terms, including “missing data,”“health-related quality of life,” and “patient-reported outcome.” Based on the meeting proceedings, the Consortium will focus on three key priorities in the coming year: developing a taxonomy of research objectives, identifying appropriate statistical methods to analyze patient-reported outcome data, and determining best practices to evaluate and deal with missing data. Conclusion The quality of the Consortium guidelines and recommendations are informed and enhanced by the broad Consortium membership which includes regulators, patients, clinicians, and academics.
Molecular and Ultrastructural Features of Diffuse Intrapulmonary Malignant Mesothelioma
Larsen, Brandon T. , Roden, Anja C. , Sukov, William R. , Thirumala, Seshadri , Colby, Thomas V. , Tazelaar, Henry D. , Smith, Maxwell L. , Hornychová, Helena , Tazelaar, Henry D.

Mayo Clinic

American Journal of Surgical Pathology | August 23, 2018 | Volume: 43 | Issue: 1 | Pages: 147-150

10.1097/pas.0000000000001143 | PMID 30138217 Get It

Obesity and Metabolic Syndrome in Kidney Transplantation: The Role of Dietary Fructose and Systemic Endotoxemia
Chan, Winnie , Stegall, Mark D. , Borrows, Richard , Stegall, Mark, Stegall, Mark D , Smith, Byron H.

Mayo Clinic

Transplantation | August 21, 2018 | Volume: 103 | Issue: 1 | Pages: 191-201

10.1097/tp.0000000000002424 | PMID 30130326 Get It

Background The concepts that obesity is merely a consequence of overeating, and that metabolic health then reflects obesity, may be insufficient and potentially flawed. The role of fructose intake and metabolic endotoxemia has gained attention recently, but data in kidney transplantation are lacking. This study evaluated the risk factors for metabolic syndrome (MS), its components, and other associated markers in kidney transplant recipients (KTRs), focusing particularly on fructose intake and systemic endotoxemia. Methods This cross-sectional observational study enrolled 128 KTRs longer than 1 year posttransplantation. Clinical, biochemical, anthropometric, and questionnaire assessments were undertaken. Results Obesity (body mass index, ≥30 kg/m2) and MS (International Diabetes Federation Definition) were found in 36.7% and 50% of KTRs, respectively. Both increased fructose intake (P = 0.01) and endotoxin level (P = 0.02) were independently associated with MS; and higher fructose intake was independently associated with obesity (P < 0.001). Specifically, increased fructose intake was associated with the central obesity (P = 0.01) and hyperglycemia (P < 0.001) criteria of MS, whereas higher endotoxin level was associated with the hypertriglyceridemia (P = 0.003) and low HDL cholesterol concentration (P = 0.002) criteria of MS. Neither saturated fat nor total caloric intakes were independently associated with obesity and MS; and neither obesity nor central obesity were independently associated with the dyslipidemia and hyperglycemia criteria of MS. Principal component analysis demonstrated relationships between higher levels of endotoxin, soluble endothelial selectin, triglycerides, and insulin resistance (r > 0.6), as well as relationships between increased fructose intake, inflammation, and blood glucose (r > 0.6). Conclusions Dietary modifications through decreasing fructose intake and addressing systemic endotoxemia are plausible targets for improving metabolic health of KTRs.